Literature DB >> 17707399

Survival and maturation of human embryonic stem cell-derived cardiomyocytes in rat hearts.

Wangde Dai1, Loren J Field, Michael Rubart, Sean Reuter, Sharon L Hale, Robert Zweigerdt, Ralph E Graichen, Gregory L Kay, Aarne J Jyrala, Alan Colman, Bruce P Davidson, Martin Pera, Robert A Kloner.   

Abstract

Human embryonic stem cell (hESC)-derived cardiomyocytes are a promising cell source for cardiac repair. Whether these cells can be transported long distance, survive, and mature in hearts subjected to ischemia/reperfusion with minimal infarction is unknown. Taking advantage of a constitutively GFP-expressing hESC line we investigated whether hESC-derived cardiomyocytes could be shipped and subsequently form grafts when transplanted into the left ventricular wall of athymic nude rats subjected to ischemia/reperfusion with minimal infarction. Co-localization of GFP-epifluorescence and cardiomyocyte-specific marker staining was utilized to analyze hESC-derived cardiomyocyte fate in a rat ischemia/reperfused myocardium. Differentiated, constitutively green fluorescent protein (GFP)-expressing hESCs (hES3-GFP; Envy) containing about 13% cardiomyocytes were differentiated in Singapore, and shipped in culture medium at 4 degrees C to Los Angeles (shipping time approximately 3 days). The cells were dissociated and a cell suspension (2 x 10(6) cells for each rat, n=10) or medium (n=10) was injected directly into the myocardium within the ischemic risk area 5 min after left coronary artery occlusion in athymic nude rats. After 15 min of ischemia, the coronary artery was reperfused. The hearts were harvested at various time points later and processed for histology, immunohistochemical staining, and fluorescence microscopy. In order to assess whether the hESC-derived cardiomyocytes might evade immune surveillance, 2 x 10(6) cells were injected into immune competent Sprague-Dawley rat hearts (n=2), and the hearts were harvested at 4 weeks after cell injection and examined as in the previous procedures. Even following 3 days of shipping, the hESC-derived cardiomyocytes within embryoid bodies (EBs) showed active and rhythmic contraction after incubation in the presence of 5% CO(2) at 37 degrees C. In the nude rats, following cell implantation, H&E, immunohistochemical staining and GFP epifluorescence demonstrated grafts in 9 out of 10 hearts. Cells that demonstrated GFP epifluorescence also stained positive (co-localized) for the muscle marker alpha-actinin and exhibited cross striations (sarcomeres). Furthermore, cells that stained positive for the antibody to GFP (immunohistochemistry) also stained positive for the muscle marker sarcomeric actin and demonstrated cross striations. At 4 weeks engrafted hESCs expressed connexin 43, suggesting the presence of nascent gap junctions between donor and host cells. No evidence of rejection was observed in nude rats as determined by inspection for lymphocytic infiltrate and/or giant cells. In contrast, hESC-derived cardiomyocytes injected into immune competent Sprague-Dawley rats resulted in an overt lymphocytic infiltrate. hESCs-derived cardiomyocytes can survive several days of shipping. Grafted cells survived up to 4 weeks after transplantation in hearts of nude rats subjected to ischemia/reperfusion with minimal infarction. They continued to express cardiac muscle markers and exhibit sarcomeric structure and they were well interspersed with the endogenous myocardium. However, hESC-derived cells did not escape immune surveillance in the xenograft setting in that they elicited a rejection phenomenon in immune competent rats.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17707399      PMCID: PMC2796607          DOI: 10.1016/j.yjmcc.2007.07.001

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  53 in total

1.  Selection of ventricular-like cardiomyocytes from ES cells in vitro.

Authors:  M Müller; B K Fleischmann; S Selbert; G J Ji; E Endl; G Middeler; O J Müller; P Schlenke; S Frese; A M Wobus; J Hescheler; H A Katus; W M Franz
Journal:  FASEB J       Date:  2000-12       Impact factor: 5.191

Review 2.  Allogeneic stem cells, clinical transplantation and the origins of regenerative medicine.

Authors:  Terry B Strom; Loren J Field; Manfred Ruediger
Journal:  Curr Opin Immunol       Date:  2002-10       Impact factor: 7.486

3.  Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation.

Authors:  Francis D Pagani; Harout DerSimonian; Agatha Zawadzka; Kristie Wetzel; Albert S B Edge; Douglas B Jacoby; Jonathan H Dinsmore; Susan Wright; Tom H Aretz; Howard J Eisen; Keith D Aaronson
Journal:  J Am Coll Cardiol       Date:  2003-03-05       Impact factor: 24.094

4.  Pluripotency of spermatogonial stem cells from adult mouse testis.

Authors:  Kaomei Guan; Karim Nayernia; Lars S Maier; Stefan Wagner; Ralf Dressel; Jae Ho Lee; Jessica Nolte; Frieder Wolf; Manyu Li; Wolfgang Engel; Gerd Hasenfuss
Journal:  Nature       Date:  2006-03-24       Impact factor: 49.962

5.  Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes.

Authors:  I Kehat; D Kenyagin-Karsenti; M Snir; H Segev; M Amit; A Gepstein; E Livne; O Binah; J Itskovitz-Eldor; L Gepstein
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

6.  Rebuilding a damaged heart: long-term survival of transplanted neonatal rat cardiomyocytes after myocardial infarction and effect on cardiac function.

Authors:  Jochen Müller-Ehmsen; Kirk L Peterson; Larry Kedes; Peter Whittaker; Joan S Dow; Tiffany I Long; Peter W Laird; Robert A Kloner
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

7.  Targeted deletion of keratins 18 and 19 leads to trophoblast fragility and early embryonic lethality.

Authors:  M Hesse; T Franz; Y Tamai; M M Taketo; T M Magin
Journal:  EMBO J       Date:  2000-10-02       Impact factor: 11.598

8.  Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells.

Authors:  Chunhui Xu; Shailaja Police; Namitha Rao; Melissa K Carpenter
Journal:  Circ Res       Date:  2002-09-20       Impact factor: 17.367

9.  Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response.

Authors:  Jeannette Nussbaum; Elina Minami; Michael A Laflamme; Jitka A I Virag; Carol B Ware; Amanda Masino; Veronica Muskheli; Lil Pabon; Hans Reinecke; Charles E Murry
Journal:  FASEB J       Date:  2007-02-06       Impact factor: 5.191

Review 10.  Embryonic stem cells share immune-privileged features relevant for tolerance induction.

Authors:  Fred Fändrich; Bettina Dresske; Michael Bader; Maren Schulze
Journal:  J Mol Med (Berl)       Date:  2002-05-16       Impact factor: 4.599

View more
  43 in total

Review 1.  Embryonic stem cells for severe heart failure: why and how?

Authors:  Philippe Menasché
Journal:  J Cardiovasc Transl Res       Date:  2012-03-13       Impact factor: 4.132

Review 2.  Potential of human embryonic stem cells in cartilage tissue engineering and regenerative medicine.

Authors:  Wei Seong Toh; Eng Hin Lee; Tong Cao
Journal:  Stem Cell Rev Rep       Date:  2011-09       Impact factor: 5.739

Review 3.  Cell tracing techniques in stem cell transplantation.

Authors:  Li Yan; Ying Han; Yuanlong He; Huahong Xie; Jingmei Liu; Lina Zhao; Jingbo Wang; Liuchun Gao; Daiming Fan
Journal:  Stem Cell Rev       Date:  2007-12       Impact factor: 5.739

Review 4.  Stem cells in the heart: what's the buzz all about? Part 2: Arrhythmic risks and clinical studies.

Authors:  Rachel Ruckdeschel Smith; Lucio Barile; Elisa Messina; Eduardo Marbán
Journal:  Heart Rhythm       Date:  2008-02-15       Impact factor: 6.343

5.  Structural coupling of cardiomyocytes and noncardiomyocytes: quantitative comparisons using a novel micropatterned cell pair assay.

Authors:  Dawn M Pedrotty; Rebecca Y Klinger; Nima Badie; Sara Hinds; Ara Kardashian; Nenad Bursac
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-23       Impact factor: 4.733

Review 6.  Cardiac applications for human pluripotent stem cells.

Authors:  Yuji Shiba; Kip D Hauch; Michael A Laflamme
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

7.  Embryonic Stem Cells as a Model for Cardiac Development and Disease.

Authors:  Todd Evans
Journal:  Drug Discov Today Dis Models       Date:  2008

8.  Long-term improvement in postinfarct left ventricular global and regional contractile function is mediated by embryonic stem cell-derived cardiomyocytes.

Authors:  Hui Qiao; Hualei Zhang; Satoshi Yamanaka; Vickas V Patel; Nataliya B Petrenko; Bin Huang; Larry R Muenz; Victor A Ferrari; Kenneth R Boheler; Rong Zhou
Journal:  Circ Cardiovasc Imaging       Date:  2010-11-08       Impact factor: 7.792

Review 9.  Induced pluripotent stem cells for cardiac repair.

Authors:  Limor Zwi-Dantsis; Lior Gepstein
Journal:  Cell Mol Life Sci       Date:  2012-07-20       Impact factor: 9.261

10.  Extracellular matrix formation after transplantation of human embryonic stem cell-derived cardiomyocytes.

Authors:  L W van Laake; E G van Donselaar; J Monshouwer-Kloots; C Schreurs; R Passier; B M Humbel; P A Doevendans; A Sonnenberg; A J Verkleij; Christine L Mummery
Journal:  Cell Mol Life Sci       Date:  2009-10-22       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.